SynDevRx, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
May 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 14, 2026The maintenance fee for Fumagillol derivatives and polymorphs thereof (US 10,287,277) comes due Nov 14, 2026. Unpaid by May 14, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for METAP2 inhibitors and methods of treating obesity (US 9,173,956) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for METAP2 inhibitors and methods of treating obesity (US 10,588,904) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (US 9,320,805) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Treatment for Tumors Driven by Metabolic Dysfunction (US 10,646,463) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,585,909 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,730,955 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,895,449 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,159,692 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,722,532 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,320,805 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,173,956 | METAP2 inhibitors and methods of treating obesity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,433,600 | METAP2 inhibitors and methods of treating obesity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,750,737 | METAP2 inhibitors and methods of treating obesity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,757,373 | MetAP2 inhibitors and methods of treating obesity In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 6 no status recorded